Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · February 22, 2023

Efficacy of Secukinumab in Patients With Moderate to Severe Hidradenitis Suppurativa

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Lancet 2023 Feb 03;[EPub Ahead of Print], AB Kimball, GBE Jemec, A Alavi, Z Reguiai, AB Gottlieb, FG Bechara, C Paul, EJ Giamarellos Bourboulis, AP Villani, A Schwinn, F Ruëff, L Pillay Ramaya, A Reich, I Lobo, R Sinclair, T Passeron, A Martorell, P Mendes-Bastos, G Kokolakis, PA Becherel, MB Wozniak, AL Martinez, X Wei, L Uhlmann, A Passera, D Keefe, R Martin, C Field, L Chen, M Vandemeulebroecke, S Ravichandran, E Muscianisi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading